IN2015DN01163A - - Google Patents
Info
- Publication number
- IN2015DN01163A IN2015DN01163A IN1163DEN2015A IN2015DN01163A IN 2015DN01163 A IN2015DN01163 A IN 2015DN01163A IN 1163DEN2015 A IN1163DEN2015 A IN 1163DEN2015A IN 2015DN01163 A IN2015DN01163 A IN 2015DN01163A
- Authority
- IN
- India
- Prior art keywords
- syndrome
- mediated
- disorder
- transportation
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261698033P | 2012-09-07 | 2012-09-07 | |
| PCT/IB2013/058318 WO2014037900A1 (en) | 2012-09-07 | 2013-09-05 | Indole carboxamide derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN01163A true IN2015DN01163A (enExample) | 2015-06-26 |
Family
ID=49585451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1163DEN2015 IN2015DN01163A (enExample) | 2012-09-07 | 2015-02-12 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9447039B2 (enExample) |
| EP (1) | EP2892880B1 (enExample) |
| JP (1) | JP6223452B2 (enExample) |
| KR (1) | KR20150048759A (enExample) |
| CN (1) | CN104603106B (enExample) |
| BR (1) | BR112015004666B1 (enExample) |
| CA (1) | CA2881351A1 (enExample) |
| EA (1) | EA028093B1 (enExample) |
| ES (1) | ES2660210T3 (enExample) |
| IN (1) | IN2015DN01163A (enExample) |
| WO (1) | WO2014037900A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015150097A1 (en) | 2014-04-04 | 2015-10-08 | Iomet Pharma Ltd | Indole derivatives for use in medicine |
| US20170044100A1 (en) * | 2014-04-22 | 2017-02-16 | The Johns Hopkins University | Inhibitors of drug-resistant mycobacterium tuberculosis |
| MX393057B (es) * | 2014-10-24 | 2025-03-24 | Bristol Myers Squibb Co | Compuestos de indol carboxamida útiles como inhibidores de cinasas. |
| US10759765B2 (en) * | 2016-04-15 | 2020-09-01 | Ce Pharm Co., Ltd. | Heterocyclic carboxylic acid amide ligand and applications thereof in copper catalyzed coupling reaction of aryl halogeno substitute |
| CN110305798B (zh) * | 2016-06-15 | 2021-11-19 | 中国医学科学院医药生物技术研究所 | 一株曲霉菌的用途及由该曲霉菌制备的化合物及其用途 |
| US10383848B2 (en) * | 2016-08-04 | 2019-08-20 | Creighton University | Indole-based therapeutics |
| US10858319B2 (en) | 2016-10-03 | 2020-12-08 | Iomet Pharma Ltd. | Indole derivatives for use in medicine |
| WO2018165614A1 (en) | 2017-03-10 | 2018-09-13 | Rutgers, The State University Of New Jersey | Bacterial efflux pump inhibitors |
| EP3592736A1 (en) | 2017-03-10 | 2020-01-15 | Rutgers, the State University of New Jersey | Indole derivatives as efflux pump inhibitors |
| WO2018165612A1 (en) | 2017-03-10 | 2018-09-13 | Rutgers, The State University Of New Jersey | Bacterial efflux pump inhibitors |
| CN111163774A (zh) | 2017-05-26 | 2020-05-15 | 罗格斯新泽西州立大学 | 细菌外排泵抑制剂 |
| US11458121B2 (en) | 2017-06-26 | 2022-10-04 | Rutgers, The State University Of New Jersey | Therapeutic compounds and methods to treat infection |
| US11718633B2 (en) | 2018-05-17 | 2023-08-08 | Council Of Scientific And Industrial Research | Indole compounds, process for the preparation and use thereof |
| KR102219563B1 (ko) * | 2019-02-15 | 2021-02-24 | 에스티팜 주식회사 | 페나진 유도체 제조를 위한 중간체 및 그의 제조방법 |
| KR20220070491A (ko) | 2019-09-26 | 2022-05-31 | 더 글로벌 얼라이언스 포 티비 드러그 디벨롭먼트, 잉크. | 미코박테리아 감염의 치료를 위한 아자인돌 카복사미드 화합물 |
| JP2022549881A (ja) * | 2019-09-26 | 2022-11-29 | ザ グローバル アライアンス フォー ティービー ドラッグ デベロップメント， インコーポレイテッド | マイコバクテリア感染症の処置のためのチアゾールカルボキサミド化合物およびその使用 |
| CN110577483B (zh) * | 2019-09-26 | 2020-05-12 | 海南医学院 | 一种3,3-二取代-2-吲哚酮的绿色合成方法 |
| KR20220069969A (ko) * | 2019-09-26 | 2022-05-27 | 더 글로벌 얼라이언스 포 티비 드러그 디벨롭먼트, 잉크. | 인돌 카복사미드 화합물 및 마이코박테리아 감염 치료를 위한 이의 용도 |
| RU2767542C1 (ru) * | 2021-05-24 | 2022-03-17 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) | Противотуберкулезное средство на основе 4-((гет)ароил)-3- гидрокси-1-(2-гидроксифенил)-5-(фенилтио)-1,5-дигидро-2Н-пиррол-2-онов |
| CN115583908B (zh) * | 2021-07-05 | 2024-08-06 | 西北农林科技大学 | 一种吲哚甲酰胺类化合物及其制备方法和用途 |
| EP4370207B1 (en) * | 2021-07-12 | 2025-12-17 | Nido Biosciences, Inc. | Bicyclic compounds as androgen receptor modulators |
| AU2023400409A1 (en) * | 2022-12-02 | 2025-06-26 | Merck Sharp & Dohme Llc | Preparation of fused azole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors |
| CN118724763B (zh) * | 2024-09-02 | 2024-12-06 | 辽宁龙田化工科技有限公司 | 一种4-甲基苯磺酰氯合成方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US883049A (en) * | 1907-09-12 | 1908-03-24 | John W Piver | Tongue-and-groove joint for flooring. |
| FR2705095B1 (fr) * | 1993-05-12 | 1995-06-23 | Adir | Nouveaux indoles substitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| HU227197B1 (en) * | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| WO2003000657A1 (en) | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Diamine derivatives |
| JP4623962B2 (ja) | 2001-10-22 | 2011-02-02 | ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク | タンパク質キナーゼおよびホスファターゼ阻害剤、それらを設計する方法、ならびにそれらを使用する方法 |
| US6759428B2 (en) | 2001-12-04 | 2004-07-06 | Roche Palo Alto Llc | Indole nitriles |
| PL370766A1 (en) | 2001-12-04 | 2005-05-30 | F.Hoffmann-La Roche Ag | Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| AU2003227360A1 (en) * | 2002-04-25 | 2003-11-10 | Yamanouchi Pharmaceutical Co., Ltd. | Novel amide derivatives or salts thereof |
| GB0428173D0 (en) * | 2004-12-23 | 2005-01-26 | Astrazeneca Ab | Compounds |
| US7825154B2 (en) * | 2005-08-12 | 2010-11-02 | The United States Of America As Represented By The Secretary Of The Army | Small molecule inhibitors of botulinum neurotoxins |
| AU2007234408B2 (en) | 2006-04-04 | 2011-05-19 | Fibrogen, Inc. | Pyrrolo- and thiazolo-pyridine compounds as HIF modulators |
| WO2009063495A2 (en) | 2007-09-20 | 2009-05-22 | Cadila Healthcare Limited | Substituted indole and its derivatives as cannabinoid modulators |
| ES2443948T3 (es) * | 2008-12-19 | 2014-02-21 | Bristol-Myers Squibb Company | Compuestos de carbazol carboxamida útiles como inhibidores de quinasas |
| WO2010099166A1 (en) | 2009-02-27 | 2010-09-02 | Siga Technologies, Inc. | Thienopyridine derivatives for the treatment and prevention of dengue virus infections |
| JP2013501003A (ja) | 2009-07-31 | 2013-01-10 | バイオクライスト ファーマシューティカルズ， インコーポレイテッド | ヤヌスキナーゼ阻害剤としてのピロロ［１，２−ｂ］ピリダジン誘導体 |
| JP5848712B2 (ja) | 2009-12-11 | 2016-01-27 | ノノ インコーポレイテッド | 虚血性疾患および他の疾患を治療するための薬剤および方法 |
| JP2012107001A (ja) * | 2010-10-22 | 2012-06-07 | Shionogi & Co Ltd | インドールアミド化合物を含有する医薬 |
| US9200046B2 (en) * | 2011-06-29 | 2015-12-01 | Cornell University | Reporter system for high throughput screening of compounds and uses thereof |
-
2013
- 2013-09-05 BR BR112015004666-5A patent/BR112015004666B1/pt not_active IP Right Cessation
- 2013-09-05 ES ES13792084.9T patent/ES2660210T3/es active Active
- 2013-09-05 EA EA201590504A patent/EA028093B1/ru not_active IP Right Cessation
- 2013-09-05 CA CA2881351A patent/CA2881351A1/en not_active Abandoned
- 2013-09-05 WO PCT/IB2013/058318 patent/WO2014037900A1/en not_active Ceased
- 2013-09-05 CN CN201380046508.9A patent/CN104603106B/zh not_active Expired - Fee Related
- 2013-09-05 JP JP2015530536A patent/JP6223452B2/ja not_active Expired - Fee Related
- 2013-09-05 US US14/420,074 patent/US9447039B2/en active Active
- 2013-09-05 KR KR1020157005663A patent/KR20150048759A/ko not_active Withdrawn
- 2013-09-05 EP EP13792084.9A patent/EP2892880B1/en not_active Not-in-force
-
2015
- 2015-02-12 IN IN1163DEN2015 patent/IN2015DN01163A/en unknown
-
2016
- 2016-08-19 US US15/242,160 patent/US20160355477A1/en not_active Abandoned
-
2020
- 2020-06-12 US US16/899,931 patent/US20210032202A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013311235A1 (en) | 2015-02-26 |
| US20160355477A1 (en) | 2016-12-08 |
| JP6223452B2 (ja) | 2017-11-01 |
| BR112015004666B1 (pt) | 2022-04-26 |
| EA201590504A1 (ru) | 2015-07-30 |
| US20210032202A1 (en) | 2021-02-04 |
| CN104603106B (zh) | 2017-05-10 |
| JP2015527388A (ja) | 2015-09-17 |
| ES2660210T3 (es) | 2018-03-21 |
| US20150175539A1 (en) | 2015-06-25 |
| KR20150048759A (ko) | 2015-05-07 |
| AU2013311235B2 (en) | 2016-03-24 |
| EP2892880B1 (en) | 2017-11-22 |
| CN104603106A (zh) | 2015-05-06 |
| EP2892880A1 (en) | 2015-07-15 |
| EA028093B1 (ru) | 2017-10-31 |
| CA2881351A1 (en) | 2014-03-13 |
| US9447039B2 (en) | 2016-09-20 |
| WO2014037900A1 (en) | 2014-03-13 |
| BR112015004666A2 (pt) | 2017-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201591527A1 (ru) | Новые производные пиридина | |
| PH12015501083B1 (en) | Novel pyridine derivatives | |
| BR112015004666A2 (pt) | derivados de indol carboxamida e usos dos mesmos | |
| MX368263B (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica. | |
| MX350539B (es) | Compuestos de enediino, conjugados de los mismos y sus usos y metodos. | |
| MY182328A (en) | Pyridine-2-amides useful as cb2 agonists | |
| PH12015501933A1 (en) | Novel pyridine derivatives | |
| MY179412A (en) | Pyridine-2-amides useful as cb2 agonists | |
| PH12015501843A1 (en) | Novel pyrazol derivatives | |
| MX349373B (es) | Nuevos derivados de pirazina. | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| MY178390A (en) | Inhibitors of iap | |
| MY180050A (en) | Novel purine derivatives | |
| MX2014008918A (es) | Nuevos derivados de pirrolidina. | |
| MX363458B (es) | Nuevos derivados de tetrazolona. | |
| PH12015500262A1 (en) | Novel pyridine derivatives | |
| MX351093B (es) | Nuevos derivados de azetidina. | |
| IN2015DN02513A (enExample) |